Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for Alzheimer’s disease, a new study shows.

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia.

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of Alzheimer’s disease for certain groups, a new study finds.